Sebastién J. Hotte

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors

Malcolm J. Moore, Holger W. Hirte, Lillian L. Siu et al. · Annals of Oncology · 2005 · 301 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study

Sebastién J. Hotte, Eric Winquist, Elizabeth B. Lamont et al. · Journal of Clinical Oncology · 2005 · 280 citations

Medicine, Oncology, Cancer Pharmacology +13

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Mark Agulnik, Ezra E.W. Cohen, Roger B. Cohen et al. · Journal of Clinical Oncology · 2007 · 263 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Walter M. Stadler, Robert A. Figlin, David F. McDermott et al. · Cancer · 2010 · 253 citations

Medicine, Oncology, Pharmacotherapy +16

Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer

Kim N., Sebastién J. Hotte, Evan Y. Yu et al. · Journal of Clinical Oncology · 2010 · 235 citations · Full text

Medicine, Oncology, Pharmacology +17